Test Price
600 AED✅ Home Collection Available
BCR-ABL Gene Rearrangement Qualitative PCR Test in UAE | 600 AED | DHA Licensed
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity through ISO 15189-accredited processing at DNA Labs UAE. This diagnostic test requires a hospital-based extraction procedure. Complimentary post-test telephonic clinical guidance is provided by our Consultant Medical Geneticist. Direct insurance billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This highly sensitive molecular test detects the BCR-ABL1 fusion gene characteristic of chronic myeloid leukemia (CML) and certain acute leukemias, providing a definitive yes/no result for the presence of the Philadelphia chromosome translocation at initial diagnosis.
| Feature | Our BCR-ABL Qualitative PCR | Closest Alternative (Quantitative PCR / FISH) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity with dual-probe RT-qPCR | Sensitivity 95-98%; potential for false negatives in low-level disease |
| Methodology | Reverse Transcription Real-Time PCR (RT-qPCR) + digital PCR confirmation upon request | Quantitative RT-PCR (reports transcript ratios) / FISH (limited by probe binding) |
| Turnaround Time | 7–10 Business Days | Often 3–5 working days, depending on lab load |
Physician Insight & Safety Protocols
A note from Consultant Medical Geneticist Lina Osama Zaki Quteineh (DHA ID: 9294403):
As a DHA-licensed Consultant Medical Geneticist specializing in molecular hematology, I emphasize that while this qualitative PCR test is a cornerstone for initial diagnosis of Philadelphia-chromosome positive leukemias, its result must be interpreted in the full context of clinical presentation, complete blood count, and bone marrow morphology. A negative result does not entirely rule out other molecular subtypes, and a positive result should be confirmed with quantitative monitoring and mutational analysis. Patient-physician communication is key to understanding the treatment pathway and avoiding anxiety.
Medication & Treatment Advisory
Do not discontinue or modify any prescribed chemotherapy, targeted agents (e.g., imatinib, dasatinib), or supportive medications without consulting your treating oncologist. The BCR-ABL qualitative test is a diagnostic aid and does not replace clinical judgment or ongoing monitoring.
Safety & Exclusion Criteria for Hospital Extraction
Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Exclusion for bone marrow aspiration: active bleeding diathesis, haemodynamic instability (requires prior stabilisation).
- ER Red Flags: sudden high fever, severe bone pain, or uncontrolled bleeding after sample collection – proceed to the nearest emergency department immediately.
- Our hospital-based phlebotomy team is trained to recognise and escalate acute symptoms during collection.
Patient FAQ & Clinical Guidance
1. What does a positive BCR-ABL qualitative PCR result mean?
A positive result confirms the presence of the BCR-ABL1 fusion gene associated with Philadelphia chromosome-positive leukemias. This finding typically indicates chronic myeloid leukaemia (CML) or a subset of acute lymphoblastic leukaemia (ALL). Further quantitative testing is needed to assess disease burden and monitor therapy.
2. How should I prepare for the BCR-ABL qualitative test?
No fasting or special preparation is required; the sample must be collected in an EDTA tube and transported refrigerated, not frozen. Our hospital logistics team handles all pre-analytical transportation to maintain cold-chain integrity. Schedule your hospital appointment and avoid strenuous exercise immediately before the extraction.
3. How accurate is this qualitative PCR compared to a bone marrow biopsy?
Our qualitative PCR offers 99.9% diagnostic sensitivity, surpassing morphological assessment in detecting minimal leukemic clones. While a bone marrow biopsy provides cellular architecture, PCR detects the BCR-ABL1 transcript at a molecular level, identifying residual disease that may be invisible under a microscope. Both tests are complementary and often used together at diagnosis.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143, strictly adhering to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient data is encrypted, access-controlled, and processed solely for clinical diagnostic purposes. Our laboratory protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability to ensure patient safety and clinical excellence.
Clinical & Logistical Metadata
| Test Name | BCR-ABL Gene Rearrangement Qualitative PCR |
| Price (AED) | 600 AED |
| Turnaround Time | 7–10 Business Days |
| Sample Type / Matrix | Whole Blood (EDTA) or Bone Marrow Aspirate (Hospital Extraction Only) |
| Methodology Used | Reverse Transcription Real-Time PCR (RT-qPCR) with p190/p210 probe sets; digital PCR confirmation available upon request. |
| ICD-10-CM Code | C92.10, C91.00, C92.00 |
| LOINC Code | 55990-1 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians